Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
memantine + donepezil (Lundbeck)
- Development stage
- Phase 4
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of memantine (administered via the Ebixa oral pump) and donepezil. Memantine is a low-to-moderate affinity, non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that binds preferentially to NMDA receptor-operated cation channels, effectively blocking the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction. Donepezil is a piperidine-based, reversible inhibitor of the enzyme acetylcholinesterase, which breaks down acetylcholine in the brain; by inhibiting this enzyme, donepezil increases the availability of acetylcholine at the synapses, potentially improving cholinergic neurotransmission. This specific combination and formulation (Ebixa oral pump as an add-on to donepezil) was evaluated in the ROMEO-AD trial (NCT02354183) conducted by Konkuk University Medical Center to assess its impact on language capability in patients with moderate to severe Alzheimer's disease.
- Brand names
- EbixaAricept
- Other names
- memantine hydrochloridedonepezil hydrochloride
02
Targets
AcetylcholinesteraseNMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on memantine + donepezil (Lundbeck).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on memantine + donepezil (Lundbeck).